Skip to main content
. Author manuscript; available in PMC: 2013 May 30.
Published in final edited form as: Am J Transplant. 2011 Nov 9;12(2):313–321. doi: 10.1111/j.1600-6143.2011.03836.x

Table 2.

Effects of F(ab’)2 and intact DSA on CAV

Group Donor Recipient Treatment Frequency of CAV p-Value
1 B10.BR B6.RAG1−/− αH-2Kk(IgG2a) 5/5
2 αH-2Kk(IgG2a) + αNK1.1 2/5 versus group 1 NS
3 F(ab’)2 fragment of αH-2Kk(IgG2a) ab + αNK1.1 0/5 versus group 1 p < 0.01
4 F(ab’)2 fragment of αH-2Kk(IgG2a) ab + αH-2Kk(IgG2a; 1 dose) 0/3
5 B6.RAG1−/− B6.RAG1−/− αH-2Kk(IgG2a) 0/6 versus group 1 p < 0.01